January/February 2010, Vol 3, No 1

Page 1

THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™ JANUARY/FEBRUARY 2010

VOLUME 3, NUMBER 1

FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS

REGULATORY

Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point? Rebecca Hyde; Diana Dobrovolny

Stakeholder Perspective by Kavita V. Nair, PhD BUSINESS

Physicians’ Perceptions of Reimbursement as a Barrier to Comprehensive Diabetes Care Alyssa Pozniak, PhD; Lois Olinger, MA; Victoria Shier, MA

Stakeholder Perspective by Gary M. Owens, MD CLINICAL

Hypertension Management: An Update Quang Nguyen, DO; Joann Dominguez, MD; Loida Nguyen, PharmD; Nageshwara Gullapalli, MD

Stakeholder Perspective by Lekshmi Dharmarajan, MD, FACP, FACC DEPARTMENTS ◆ Generic Drug Trends

Competition from Biosimilars an Incentive for Innovation ◆ Industry Trends

Emerging Trends in Breast Cancer Management ◆ Drug Pipeline

Rheumatology Pipeline Boasts Innovation, ID Line Is Drying Up: ACR/IDSA 2009 Cardiology Pipeline Is Promising: AHA 2009

©2010 Engage Healthcare Communications, LLC www.AHDBonline.com


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
January/February 2010, Vol 3, No 1 by Dalia Buffery - Issuu